Rodon Biologics provides excellence in the development of biopharmaceutical products for third parties.

Rodon Biologics is a biotechnology CRO/CDMO with over 20 years of experience delivering tailored protein solutions for discovery research, preclinical development, and early-stage manufacturing. The company specializes in the engineering, production, analysis, and characterization of recombinant proteins, as well as small molecules produced using engineered microorganisms.
Founded in 1999, Rodon provides integrated services supporting discovery, early-stage research, preclinical development, and manufacturing. Its expertise spans recombinant protein production using E. coli, yeast, and mammalian cell expression systems, enabling flexible solutions across multiple biologic modalities.
The company supports projects from DNA to drug product, offering protein engineering, expression, purification, and characterization services for quantities ranging from a few milligrams to tens of grams. Development capabilities also include stable cell line generation and scalable process development to facilitate technology transfer and clinical manufacturing.
Working in collaboration with GMP manufacturing partners, Rodon helps clients advance biologics from early research through clinical development with robust, scalable processes and comprehensive technical support.